Virus injection plus immunotherapy and targeted drug for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing a new combination: a virus injected directly into the tumor, plus two drugs (tislelizumab and lenvatinib) that boost the immune system and block tumor blood supply. It is for people with advanced liver cancer who have not had similar treatments before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced liver cancer that has not spread to the brain or caused serious liver failure.
- You have not had prior immunotherapy or targeted therapy for your liver cancer.
- Your liver is working fairly well (Child-Pugh score ≤7, which is a measure of liver function).
- You have at least one liver tumor that is large enough to be measured on a scan (≥1 cm).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
This Phase 2 trial studies whether adding a cancer vaccine (to help the immune system recognize your tumor) to two medicines—atezolizumab and bevacizumab—can better control unresectable or advanced liver cancer. It’s for people who haven’t had prior whole-body (systemic) cancer treatment.
This trial tests if removing the main liver tumor with surgery, followed by targeted therapy and immunotherapy, can help people with advanced liver cancer that has spread a little. It is for those who have not had prior treatment and whose liver is still working well.
This trial tests a new sequence of treatments for advanced liver cancer that hasn't been treated before. It uses a virus therapy (H101) delivered directly to the liver through a small tube, followed by two drugs (T and I) to shrink tumors and help your immune system fight the cancer.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.